Cargando…

Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis

To reduce potentially inappropriate medications, the FORTA (Fit fOR The Aged) concept classifies drugs in terms of their suitability for geriatric patients with different labels, namely A (indispensable), B (beneficial), C (questionable), and D (avoid). The aims of our study were to assess the medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Greten, S., Müller-Funogea, J. I., Wegner, F., Höglinger, G. U., Simon, N., Junius-Walker, U., Gerbel, S., Krause, O., Klietz, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815558/
https://www.ncbi.nlm.nih.gov/pubmed/33263172
http://dx.doi.org/10.1007/s00702-020-02276-x
_version_ 1783638254524825600
author Greten, S.
Müller-Funogea, J. I.
Wegner, F.
Höglinger, G. U.
Simon, N.
Junius-Walker, U.
Gerbel, S.
Krause, O.
Klietz, M.
author_facet Greten, S.
Müller-Funogea, J. I.
Wegner, F.
Höglinger, G. U.
Simon, N.
Junius-Walker, U.
Gerbel, S.
Krause, O.
Klietz, M.
author_sort Greten, S.
collection PubMed
description To reduce potentially inappropriate medications, the FORTA (Fit fOR The Aged) concept classifies drugs in terms of their suitability for geriatric patients with different labels, namely A (indispensable), B (beneficial), C (questionable), and D (avoid). The aims of our study were to assess the medication appropriateness in PD inpatients applying the FORTA list and drug-drug interaction software, further to assess the adequacy of FORTA list for patients with PD. We retrospectively collected demographic data, comorbidities, laboratory values, and the medication from the discharge letters of 123 geriatric inpatients with PD at the university hospital of Hannover Medical School. Patients suffered on average from 8.2 comorbidities. The majority of the medication was labeled A (60.6% of PD-specific and 40.9% of other medication) or B (22.3% of PD-specific and 26.9% of other medication). Administered drugs labeled with D were amantadine, clozapine, oxazepam, lorazepam, amitriptyline, and clonidine. Overall, 545 interactions were identified, thereof 11.9% severe interactions, and 1.7% contraindicated combinations. 81.3% of patients had at least one moderate or severe interaction. The FORTA list gives rational recommendations for PD-specific and other medication, especially for general practitioners. Considering the demographic characteristics and the common multimorbidity of geriatric PD patients, this study underlines the importance of awareness, education, and preventive interventions to increase drug safety.
format Online
Article
Text
id pubmed-7815558
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-78155582021-01-25 Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis Greten, S. Müller-Funogea, J. I. Wegner, F. Höglinger, G. U. Simon, N. Junius-Walker, U. Gerbel, S. Krause, O. Klietz, M. J Neural Transm (Vienna) Neurology and Preclinical Neurological Studies - Original Article To reduce potentially inappropriate medications, the FORTA (Fit fOR The Aged) concept classifies drugs in terms of their suitability for geriatric patients with different labels, namely A (indispensable), B (beneficial), C (questionable), and D (avoid). The aims of our study were to assess the medication appropriateness in PD inpatients applying the FORTA list and drug-drug interaction software, further to assess the adequacy of FORTA list for patients with PD. We retrospectively collected demographic data, comorbidities, laboratory values, and the medication from the discharge letters of 123 geriatric inpatients with PD at the university hospital of Hannover Medical School. Patients suffered on average from 8.2 comorbidities. The majority of the medication was labeled A (60.6% of PD-specific and 40.9% of other medication) or B (22.3% of PD-specific and 26.9% of other medication). Administered drugs labeled with D were amantadine, clozapine, oxazepam, lorazepam, amitriptyline, and clonidine. Overall, 545 interactions were identified, thereof 11.9% severe interactions, and 1.7% contraindicated combinations. 81.3% of patients had at least one moderate or severe interaction. The FORTA list gives rational recommendations for PD-specific and other medication, especially for general practitioners. Considering the demographic characteristics and the common multimorbidity of geriatric PD patients, this study underlines the importance of awareness, education, and preventive interventions to increase drug safety. Springer Vienna 2020-12-01 2021 /pmc/articles/PMC7815558/ /pubmed/33263172 http://dx.doi.org/10.1007/s00702-020-02276-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Neurology and Preclinical Neurological Studies - Original Article
Greten, S.
Müller-Funogea, J. I.
Wegner, F.
Höglinger, G. U.
Simon, N.
Junius-Walker, U.
Gerbel, S.
Krause, O.
Klietz, M.
Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
title Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
title_full Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
title_fullStr Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
title_full_unstemmed Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
title_short Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
title_sort drug safety profiles in geriatric patients with parkinson’s disease using the forta (fit for the aged) classification: results from a mono-centric retrospective analysis
topic Neurology and Preclinical Neurological Studies - Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815558/
https://www.ncbi.nlm.nih.gov/pubmed/33263172
http://dx.doi.org/10.1007/s00702-020-02276-x
work_keys_str_mv AT gretens drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis
AT mullerfunogeaji drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis
AT wegnerf drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis
AT hoglingergu drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis
AT simonn drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis
AT juniuswalkeru drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis
AT gerbels drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis
AT krauseo drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis
AT klietzm drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis